- Phase I Clinical Trial of Prostate-Specific Membrane Antigen-Targeting 68 Ga-NGUL PET/CT in Healthy Volunteers and Patients with Prostate Cancer
-
Suh M, Ryoo HG, Kang KW, Jeong JM, Jeong CWJ, Kwak C, Cheon GJ
- KMID: 2532658
- Korean J Radiol.
- 2022 Sep;23(9):911-920.
- doi: 10.3348/kjr.2022.0176
Objective: 68 Ga-NGUL is a novel prostate-specific membrane antigen (PSMA)-targeting tracer based on Glu-Urea-Lys derivatives conjugated to a 1,4,7-triazacyclononane-N,N’,N’’-triacetic acid (NOTA) chelator via a thiourea-type short linker. This phase I... -
- CITED
-
- Close
- SHARE
-
- Close
